Structure Therapeutics(US:GPCR) Globenewswireยท2025-11-06 21:01Core Insights - Structure Therapeutics is on track to report topline data from the ACCESS and ACCESS II studies of aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity treatment, by year-end 2025 [2][3] - The company plans to initiate a Phase 1 study for ACCG-2671, an oral amylin receptor agonist, by year-end 2025, and has declared a second candidate, ACCG-3535, to strengthen its pipeline [2][11] - As of September 30, 2025, the company has a strong financial position with cash, cash equivalents, and short-term investments totaling $799.0 million, expected to fund operations through at least 2027 [5][9] Research and Development Updates - The ACCESS study is a Phase 2b trial involving approximately 220 adults with obesity or overweight, evaluating doses of aleniglipron up to 120 mg [3] - The ACCESS II study includes around 80 adults and is assessing higher doses of aleniglipron (180 mg and 240 mg) with an extended evaluation period [3] - Additional studies are ongoing to support the competitive positioning of aleniglipron and to prepare for Phase 3 trials, including a body composition study and a study in patients with type 2 diabetes mellitus [3] Financial Performance - R&D expenses for Q3 2025 were $59.0 million, up from $32.6 million in Q3 2024, primarily due to increased clinical trial costs and personnel expenses [6] - G&A expenses rose to $14.8 million in Q3 2025 from $13.2 million in Q3 2024, reflecting the expansion of the company's infrastructure [7] - The net loss for Q3 2025 was $65.7 million, compared to a net loss of $34.0 million in Q3 2024 [8][13]